Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1

Journal of Hepatology

Volumn 56, Issue 3, 2012, Pages 557-563

  Howell, Charles D ^a   Gorden, Alexis ^a   Ryan, Kathleen A ^a   Thompson, Alexander J ^b   Ibrahim, Chadi ^a   Fried, Michael ^c   Afdhal, Nezam H ^d   McHutchison, John G ^b   Shianna, Kevin V ^e   Goldstein, David B ^e   Shuldiner, Alan R ^a   Mitchell, Braxton D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e DUKE UNIVERSITY   (United States)

Author keywords

Hepatitis C virus; IL28B gene; Single nucleotide polymorphism; Viral kinetics

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AFRICA; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE TRANSITION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; ANTIVIRAL AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL;

EID: 84857363815     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.10.004     Document Type: Article

References (21)

1. S. Maylin, M. Martinot-Peignoux, R. Moucari, N. Boyer, M.P. Ripault, and D. Cazals-Hatem Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 3 2008 821 829
2. P. Pradat, H.L. Tillmann, S. Sauleda, J.H. Braconier, G. Saracco, and M. Thursz Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications J Viral Hepat 8 2007 556 563
3. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 2001 958 965
4. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Peginterferon alfa-2a plus ribavirin for chronic hepatitis C N Engl J Med 2002 975 982
5. H.S. Conjeevaram, M.W. Fried, L.J. Jeffers, N. Terrault, T. Wiley-Lucas, and N. Afdhal Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients with Chronic Hepatitis C Genotype 1 Gastroenterology 2006 470 477
6. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 7262 2009 399 401
7. J.H. Hoofnagle, A.S. Wahed, R.S. Brown Jr., C.D. Howell, S.H. Belle, and Virahep-C Study Group Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection J Infect Dis 8 2009 1112 1120
8. J.E. Layden, T.J. Layden, K.R. Reddy, R.S. Levy-Drummer, J. Poulakos, and A.U. Neumann First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline J Viral Hepat 2002 340 345
9. C. Girard, M. Ravallec, M. Mariller, J.P. Bossy, A. Cahour, and M. Lopez-Ferber Effect of the 5′ non-translated region on self-assembly of hepatitis C virus genotype 1a structural proteins produced in insect cells J Gen Virol 0 2004 3659 3670
10. E. Herrmann, J.H. Lee, G. Marinos, M. Modi, and S. Zeuzem Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon Hepatology 2003 1351 1358
11. H. Dahari, R.M. Ribeiro, and A.S. Perelson Triphasic decline of hepatitis C virus RNA during antiviral therapy Hepatology 1 2007 16 21
12. J.E. Layden-Almer, R.M. Ribeiro, T. Wiley, A.S. Perelson, and T.J. Layden Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin Hepatology 2003 1343 1350
13. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, and K.V. Shianna Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 1 2010 120 129 [e18]
14. P.Y. Bochud, S. Bibert, F. Negro, B. Haagmans, A. Soulier, and C. Ferrari IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C J Hepatol 2011
15. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 18 2009 1827 1838
16. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, and M.P. Manns Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 13 2011 1195 1206
17. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, and C. O'huigin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 2009
18. J.J. Feld, G.A. Lutchman, T. Heller, K. Hara, J.K. Pfeiffer, and R.D. Leff Ribavirin improves early responses to peginterferon through improved interferon signaling Gastroenterology 1 2010 154 162 [e4]
19. J.J. McCarthy, J.H. Li, A. Thompson, S. Suchindran, X.Q. Lao, and K. Patel Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin Gastroenterology 7 2010 2307 2314
20. D. Howell C, T.C. Dowling, M. Paul, A.S. Wahed, N.A. Terrault, and M. Taylor Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection Clin Gastroenterol Hepatol 5 2008 575 583
21. N.M. Dixit, J.E. Layden-Almer, T.J. Layden, and A.S. Perelson Modelling how ribavirin improves interferon response rates in hepatitis C virus infection Nature 2004 922 924